Expecting very active 2026 from a clinical perspective, including significant patient accrual completions and subsequent data readouts from ...

During the first half of 2025, our portfolio was up 4.2% in Canadian dollars net of fees which brings our return since inception to +66.3% in Canadian dollars net of fees. Eight out of Ten (81%) of ...